
Leonie Saft

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481957/publications.pdf Version: 2024-02-01



LEONIE SAET

#	Article	IF	CITATIONS
1	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 2014, 99, 1041-1049.	1.7	116
2	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	1.7	74
3	SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Blood, 2017, 130, 881-890.	0.6	66
4	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, 102, 498-508.	1.7	34
5	Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes. Leukemia Research, 2013, 37, 266-273.	0.4	33
6	Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. American Journal of Hematology, 2016, 91, 1234-1238.	2.0	32
7	<scp>CD</scp> 274 (<scp>PD</scp> â€1)/ <scp>PDCD</scp> 1 (<scp>PD</scp> â€1) expression in de novo and transformed diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2018, 180, 744-748.	1.2	22
8	The AML–MDS interface—leukemic transformation in myelodysplastic syndromes. Journal of Hematopathology, 2011, 4, 69-79.	0.2	19
9	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	0.7	18
10	Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features. Oncoscience, 2014, 1, 550-557.	0.9	17
11	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp> . Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	0.7	16
12	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. American Journal of Clinical Pathology, 2021, 155, 179-210.	0.4	13
13	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Annals of Hematology, 2017, 96, 1105-1112.	0.8	11
14	Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. Leukemia Research, 2018, 71, 75-81.	0.4	11
15	The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single enter analysis of 79 patients. Cytometry Part B - Clinical Cytometry, 2020, 98, 250-258.	0.7	10
16	Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 604-613.	0.6	7
17	Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification. Journal of Hematopathology, 2020, 13, 79-88.	0.2	6
18	"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)― Leukemia, 2022, 36, 1436-1439.	3.3	6

LEONIE SAFT

#	Article	IF	CITATIONS
19	A series of case studies illustrating the role of flow cytometry in the diagnostic workâ€up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	0.7	5
20	Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment. British Journal of Haematology, 2018, 180, 526-533.	1.2	3
21	Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group. Pathobiology, 2019, 86, 62-75.	1.9	3
22	p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study. Blood, 2014, 124, 414-414.	0.6	3
23	Intracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review. Journal of Hematopathology, 2022, 15, 13-19.	0.2	2
24	Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression. Blood, 2008, 112, 5104-5104.	0.6	1
25	Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment. Blood, 2011, 118, 790-790.	0.6	Ο
26	Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,. Blood, 2011, 118, 3798-3798.	0.6	0
27	The Diagnostic Role of Flow Cytometry in Idiopathic Cytopenia of Unknown Significance (ICUS): A Single-Center Analysis of 79 Patients. Blood, 2018, 132, 3105-3105.	0.6	Ο
28	From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival. Blood, 2018, 132, 794-794.	0.6	0
29	Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment. Acta Oncológica, 2022, 61, 824-829.	0.8	Ο